News | July 08, 2025
Everest Medicines progresses in AI-powered mRNA platform at 2025 R&D day
The company showcased three core programs developed through this platform
The company showcased three core programs developed through this platform
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Granules India receives 1 observation from USFDA for Chantilly facility
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
Sun Pharma gets 8 observations from USFDA for Halol facility
Zydus receives EIR for the API manufacturing facility at Ankleshwar
Subscribe To Our Newsletter & Stay Updated
